{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".278","upperLimit":".604","value":".436"},{"groupId":"OG001","lowerLimit":".460","upperLimit":".782","value":".632"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"ORR is defined as partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) according to International Myeloma Working Group (IMWG) Uniform Response Criteria","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.","id":"OG000","title":"Arm I (Pomalidomide, Dexamethasone)"},{"description":"Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Pomalidomide, Dexamethasone, Ixazomib)"}],"paramType":"NUMBER","populationDescription":"All eligible and treated Phase II patients were included in analysis. Phase I patients were excluded from response analysis.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}